The presynaptic alpha-2 autoreceptors in pig brain cortex are alpha-2A. 1996

A U Trendelenburg, and N Limberger, and K Starke
Pharmakologisches Institut, Freiburg, Germany.

The presynaptic alpha-2 autoreceptors in pig brain cortex were subclassified in terms of alpha-2A, alpha-2B, alpha-2C and alpha-2D to test the hypothesis that alpha-2 autoreceptors belong predominantly to the alpha-2A/D pair of orthologous alpha-2 adrenoceptors. Slices of brain cortex were preincubated with [3H]norepinephrine and then superfused and stimulated electrically. pKd values of 13 alpha-2 adrenoceptor antagonists (including the partial agonist oxymetazoline) against the alpha-2 agoinst 5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline (UK 14,304) were determined. The stimulation periods used (six pulses at 100 Hz) did not lead to alpha-2 autoinhibition, as shown by the failure of all but one of the alpha-2 antagonists to increase the stimulation-evoked overflow of tritium. UK 14,304 caused a concentration-dependent decrease of the evoked overflow of tritium, with an EC50 value of 0.90 nM and a maximal inhibition of 95.2%. All antagonists shifted the concentration-inhibition curve of UK 14,304 to the right in a parallel manner. Antagonist pKd values were calculated from the shifts. The pKd values at the presynaptic alpha-2 autoreceptors in pig brain cortex correlated excellently with pKd values at previously subclassified alpha-2A sites but did not correlate significantly or correlated much less well with pKd values at alpha-2B, alpha-2C and alpha-2D sites. Also, ratios of Kd values of the antagonists at the presynaptic alpha-2 autoreceptors in pig brain cortex agreed well with ratios at previously subclassified alpha-2A sites but not with those at previously subclassified alpha-2B-D sites. It is concluded that the alpha-2 autoreceptors in pig brain cortex are alpha-2A, in accordance with the hypothesis mentioned.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011810 Quinoxalines Quinoxaline
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D000068438 Brimonidine Tartrate A quinoxaline derivative and ADRENERGIC ALHPA-2 RECEPTOR AGONIST that is used to manage INTRAOCULAR PRESSURE associated with OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION. 5-Bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate,5-bromo-6-(imidazolidinylideneamino)quinoxaline,5-bromo-6-(imidazolin-2-ylamino)quinoxaline,AGN 190342,AGN-190342,Alphagan,Alphagan P,Brimonidine,Brimonidine Purite,Brimonidine Tartrate (1:1),Brimonidine Tartrate (1:1), (S-(R*,R*))-Isomer,Brimonidine Tartrate, (R-(R*,R*))-Isomer,Bromoxidine,Mirvaso,Ratio-Brimonidine,Sanrosa,UK 14,304,UK 14,304-18,UK 14304,UK 14308,UK-14,304-18,UK-14,308,UK-14304,AGN190342,Ratio Brimonidine,UK 14,304 18,UK 14,30418,UK 14,308,UK14,30418,UK14,308,UK14304
D000316 Adrenergic alpha-Agonists Drugs that selectively bind to and activate alpha adrenergic receptors. Adrenergic alpha-Receptor Agonists,alpha-Adrenergic Receptor Agonists,Adrenergic alpha-Agonist,Adrenergic alpha-Receptor Agonist,Receptor Agonists, Adrenergic alpha,Receptor Agonists, alpha-Adrenergic,alpha-Adrenergic Agonist,alpha-Adrenergic Agonists,alpha-Adrenergic Receptor Agonist,Adrenergic alpha Agonist,Adrenergic alpha Agonists,Adrenergic alpha Receptor Agonist,Adrenergic alpha Receptor Agonists,Agonist, Adrenergic alpha-Receptor,Agonist, alpha-Adrenergic,Agonist, alpha-Adrenergic Receptor,Agonists, Adrenergic alpha-Receptor,Agonists, alpha-Adrenergic,Agonists, alpha-Adrenergic Receptor,Receptor Agonist, alpha-Adrenergic,Receptor Agonists, alpha Adrenergic,alpha Adrenergic Agonist,alpha Adrenergic Agonists,alpha Adrenergic Receptor Agonist,alpha Adrenergic Receptor Agonists,alpha-Agonist, Adrenergic,alpha-Agonists, Adrenergic,alpha-Receptor Agonist, Adrenergic,alpha-Receptor Agonists, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013552 Swine Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA). Phacochoerus,Pigs,Suidae,Warthogs,Wart Hogs,Hog, Wart,Hogs, Wart,Wart Hog
D017660 Autoreceptors Transmitter receptors on or near presynaptic terminals (or varicosities) which are sensitive to the transmitter(s) released by the terminal itself. Receptors for the hormones released by hormone-releasing cells are also included. Autoreceptor
D017729 Presynaptic Terminals The distal terminations of axons which are specialized for the release of neurotransmitters. Also included are varicosities along the course of axons which have similar specializations and also release transmitters. Presynaptic terminals in both the central and peripheral nervous systems are included. Axon Terminals,Nerve Endings, Presynaptic,Synaptic Boutons,Synaptic Terminals,Axon Terminal,Bouton, Synaptic,Boutons, Synaptic,Ending, Presynaptic Nerve,Endings, Presynaptic Nerve,Nerve Ending, Presynaptic,Presynaptic Nerve Ending,Presynaptic Nerve Endings,Presynaptic Terminal,Synaptic Bouton,Synaptic Terminal,Terminal, Axon,Terminal, Presynaptic,Terminal, Synaptic,Terminals, Axon,Terminals, Presynaptic,Terminals, Synaptic

Related Publications

A U Trendelenburg, and N Limberger, and K Starke
March 1997, Naunyn-Schmiedeberg's archives of pharmacology,
A U Trendelenburg, and N Limberger, and K Starke
May 1991, British journal of pharmacology,
A U Trendelenburg, and N Limberger, and K Starke
July 1988, Naunyn-Schmiedeberg's archives of pharmacology,
A U Trendelenburg, and N Limberger, and K Starke
January 1987, Reviews of physiology, biochemistry and pharmacology,
A U Trendelenburg, and N Limberger, and K Starke
February 1996, Naunyn-Schmiedeberg's archives of pharmacology,
A U Trendelenburg, and N Limberger, and K Starke
December 1989, Naunyn-Schmiedeberg's archives of pharmacology,
A U Trendelenburg, and N Limberger, and K Starke
December 1992, British journal of pharmacology,
A U Trendelenburg, and N Limberger, and K Starke
July 1990, Journal of cardiovascular pharmacology,
A U Trendelenburg, and N Limberger, and K Starke
July 1989, Naunyn-Schmiedeberg's archives of pharmacology,
A U Trendelenburg, and N Limberger, and K Starke
April 1996, European journal of pharmacology,
Copied contents to your clipboard!